AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Choline transporter-like protein 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q53GD3

UPID:

CTL4_HUMAN

Alternative names:

Solute carrier family 44 member 4; Thiamine pyrophosphate transporter 1

Alternative UPACC:

Q53GD3; A2BED3; B0UXX8; B0UZY8; B4DU94; B4DWM2; E9PEK7; Q5JP84; Q5JQ93; Q658S8; Q6UX89; Q8TEW4; Q96C58; Q96K59; Q9Y332

Background:

Choline transporter-like protein 4, also known as Solute carrier family 44 member 4 and Thiamine pyrophosphate transporter 1, plays a crucial role in the choline-acetylcholine system. It is essential for the efferent innervation of hair cells in the olivocochlear bundle, maintaining the physiological function of outer hair cells and protecting them from acoustic injury. Additionally, it functions as a thiamine pyrophosphate transporter in the colon, contributing to host thiamine homeostasis.

Therapeutic significance:

The protein's involvement in Deafness, autosomal dominant, 72, a form of non-syndromic sensorineural hearing loss affecting middle frequencies, highlights its potential as a target for therapeutic intervention. Understanding the role of Choline transporter-like protein 4 could open doors to novel treatments for hearing loss and thiamine deficiency disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.